InterpaceBiosciences_New Logo.png
Interpace Pharma Solutions Announces New Capability in Spatial Biology/Precision Oncology Services
May 17, 2021 08:00 ET | Interpace Biosciences, Inc.
Parsippany, NJ, May 17, 2021 (GLOBE NEWSWIRE) -- Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that it will...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces First Quarter 2021 Financial and Business Results
May 11, 2021 16:47 ET | Interpace Biosciences, Inc.
 ● Q1 Revenue of $9.8 Million is Company’s Highest as Combined Molecular Diagnostics and Pharma Services Business  ● Q2 Revenue Expected to Exceed $11 million  ● On Track to Exceed Full Year 2021...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces Improved Coverage for ThyGeNEXT® and ThyraMIR®
May 03, 2021 08:00 ET | Interpace Biosciences, Inc.
Parsippany, NJ, May 03, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that eviCore Healthcare (“eviCore”), a wholly owned...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Raises Full Year 2021 Revenue Guidance
April 19, 2021 07:05 ET | Interpace Biosciences, Inc.
Parsippany, NJ, April 19, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced an update to its full year 2021 revenue guidance...
InterpaceBiosciences_New Logo.png
Interpace Pharma Solutions Announces New Advanced Offering in RNA Biomarker Analysis
April 12, 2021 07:05 ET | Interpace Biosciences, Inc.
Parsippany, NJ, April 12, 2021 (GLOBE NEWSWIRE) -- Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today new capability...
LOGO.jpg
Interpace Biosciences Announces New PLA Code and Medicare Reimbursement Increase for Proprietary Thyroid Assay, ThyGeNEXT®
April 05, 2021 16:05 ET | Interpace Biosciences, Inc.
Parsippany, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that Novitas, its Medicare Administrative Contractor, has...
LOGO.jpg
Interpace Biosciences Announces Acceptance for Trading on the OTCQX
February 24, 2021 17:54 ET | Interpace Biosciences, Inc.
PARSIPPANY, NJ, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace Biosciences” or the “Company”), an emerging leader in enabling personalized medicine, today...
LOGO.jpg
Interpace Biosciences Announces Impending Delisting from Nasdaq
February 17, 2021 08:00 ET | Interpace Biosciences, Inc.
PARSIPPANY, NJ, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, today announced that on...
LOGO.jpg
Interpace Biosciences Announces CFO Leadership Transition
February 04, 2021 16:42 ET | Interpace Biosciences, Inc.
PARSIPPANY, NJ, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”) a leader in enabling personalized medicine, announced today that its Board of Directors has...
LOGO.jpg
Interpace Biosciences Announces License Agreement with Rutgers University and Mass General Hospital
February 01, 2021 09:27 ET | Interpace Biosciences, Inc.
Parsippany, NJ, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) announced today that it has executed a license agreement with Rutgers, The State University of New...